| Description |
1 online resource (x, 234 pages) : illustrations |
| Series |
Current topics in microbiology and immunology, 0070-217X ; v. 355 |
|
Current topics in microbiology and immunology ; v. 355. 0070-217X
|
| Contents |
Setting up a Kinase Discovery and Development Project / Gideon Bollag -- Drug Efficacy Testing in Mice / William Y. Kim, Norman E. Sharpless -- Gastrointestinal Stromal Tumors / Cristina Antonescu -- EGFR Mutant Lung Cancer / Yixuan Gong, William Pao -- Targeting Oncogenic BRAF in Human Cancer / Christine A. Pratilas, Feng Xing, David B. Solit -- Beyond BRAF in Melanoma / Adil Daud, Boris C. Bastian -- JAK-Mutant Myeloproliferative Neoplasms / Ross L. Levine -- Will Kinase Inhibitors Make it as Glioblastoma Drugs? / Ingo K. Mellinghoff, Nikolaus Schultz, Paul S. Mischel -- Predictive Genomic Biomarkers / Rakesh Kumar, Rafael G. Amado -- Epigenetic Biomarkers / Timothy A. Chan, Stephen B. Baylin -- Adjuvant Trials of Targeted Agents: The Newest Battleground in the War on Cancer / Robert L. Cohen |
| Summary |
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as "chemotherapy" and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors hope these lessons will be instructive for the novice as well as the expert |
| Analysis |
biomedische wetenschappen |
|
biomedicine |
|
neoplasms |
|
Medicine (General) |
|
Geneeskunde (algemeen) |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record |
| Subject |
Cancer -- Chemotherapy.
|
|
Antineoplastic agents.
|
|
Neoplasms -- drug therapy
|
|
Protein Kinase Inhibitors -- therapeutic use
|
|
Antineoplastic Agents -- therapeutic use
|
|
Drug Discovery
|
|
Adenosine Triphosphate -- therapeutic use
|
|
MEDICAL -- Pharmacology.
|
|
Antineoplastic agents
|
|
Cancer -- Chemotherapy
|
| Form |
Electronic book
|
| Author |
Mellinghoff, Ingo K
|
|
Sawyers, Charles L
|
| ISBN |
9783642282966 |
|
3642282962 |
|
9781283865258 |
|
1283865254 |
|
